

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA ISOTOPE & RADIATION CORPORATION**

**中國同輻股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1763)**

### **ANNOUNCEMENT**

### **POSITIVE PROFIT ALERT**

This announcement is made by China Isotope & Radiation Corporation (the **“Company”**, together with its subsidiaries referred to as the **“Group”**) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **“Hong Kong Listing Rules”**) and the Inside Information Provisions (as defined under the Hong Kong Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the **“Board”**) wishes to inform the shareholders of the Company and potential investors that, based on a preliminary review on the unaudited consolidated management accounts of the Group for the year ended 31 December 2022 and information currently available, the revenue is expected to be approximately RMB 6,020 million to RMB 6,270 million, representing a year-on-year increase of approximately 17% to 22%, and the profit for the year attributable to equity shareholders of the Company is expected to be approximately RMB 376 million to RMB 399 million, representing a year-on-year increase of approximately 13% to 19% as compared with those for the same period in 2021. The growth in revenue and profit for the year of 2022 is mainly due to the stable growth of the Group's pharmaceuticals business and radioactive sources business, as well as the rapid growth of its radiation therapy equipment business.

The Company is in the process of finalising the Group's consolidated results for the year ended 31 December 2022. The information contained in this announcement is only based on the unaudited consolidated management accounts of the Group and the information currently available to the Board, which have not been reviewed or audited by the Company's auditors or the Audit and Risk Management Committee. The actual results of the Group for the year ended 31 December 2022 may differ from the information contained in this announcement. The announcement of the Group's annual results for the year ended 31 December 2022 is expected to be published by the end of March 2023.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**China Isotope & Radiation Corporation**  
**Wang Suohui**  
*Chairman*

Beijing, the PRC, 15 January 2023

*As at the date of this announcement, the Board comprises Mr. Wang Suohui, Mr. Xu Hongchao and Mr. Du Jin as executive Directors; Mr. Chen Shoulei, Mr. Dai Shuquan, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Hui Wan Fai, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.*